Novartis Inc

NOVN

Equity

ISIN CH0012005267 / Valor 1200526

SIX Swiss Exchange (2024-11-20)

CHF 90.99-0.08%

Novartis Inc
UMushroom community rating:

4.00 8 votes No rating yet

NegativeNeutralPositive

About company

Novartis Inc. is a global healthcare company that specializes in the development and distribution of innovative medicines. With a focus on addressing unmet medical needs, Novartis aims to improve and extend the lives of people suffering from serious diseases. The company operates in several core therapeutic areas, including cardiovascular, renal and metabolic diseases, immunology, neuroscience, and oncology. Novartis is known for its commitment to research and development, leveraging advanced technology platforms to create groundbreaking therapies. With a workforce of approximately 78,000 employees representing over 140 nationalities, Novartis has a significant global presence, reaching more than 284 million patients worldwide. The company's strategy revolves around delivering high-value medicines and employing novel access approaches to alleviate some of society's most significant disease burdens.

Summarized from source with an LLMView SourceSector: Healthcare

Q2 2024 Net Sales

In Q2 2024, Novartis Inc. reported net sales of USD 12,512 million, reflecting a 9% increase compared to Q2 2023. When adjusted for constant currencies (cc), the growth rate was 11%.

Q2 2024 Operating Income

Novartis Inc.'s operating income for Q2 2024 was USD 4,014 million, a significant 43% increase from the USD 2,807 million reported in Q2 2023. On a constant currency basis, the growth was even higher at 47%.

Q2 2024 Net Income

The net income for Novartis Inc. in Q2 2024 stood at USD 3,246 million, marking a 43% rise from the USD 2,271 million recorded in Q2 2023. Adjusted for constant currencies, the net income growth was 49%.

Q2 2024 Earnings Per Share (EPS)

Novartis Inc. reported an EPS of USD 1.60 for Q2 2024, up 47% from USD 1.09 in Q2 2023. On a constant currency basis, the EPS growth was 52%.

Q2 2024 Free Cash Flow

In Q2 2024, Novartis Inc. generated a free cash flow of USD 4,615 million, which represents a 40% increase compared to the USD 3,292 million reported in Q2 2023.

Summarized from source with an LLMView Source

Key figures

7.96%1Y

26.3%3Y

6.84%5Y

Performance

17.0%1Y

17.7%3Y

19.0%5Y

Volatility